A new preprint links the company’s cell therapy to less brain inflammation in Alzheimer’s, just as it heads out on an ...

All three Phase 3 trials of the weekly shot ribupatide have finished enrolling, and the head-to-head against semaglutide is ...

Patent cliffs and falling R&D productivity push the biggest players toward other people's science – our report puts numbers ...

Monte Rosa’s NEK7-targeting drug pulled several heart-risk biomarkers toward healthy levels in 108 people with obesity.

Mighty Therapeutics and the University of Washington will use pilot data on elamipretide to design a larger trial in older ...

A Lancet Neurology study of 130 blood proteins in patients receiving lecanemab suggests amyloid clearance and cognitive ...

Lovehoney’s hormone-free MenoPulse device launches, pairing air-pulse tech with early data on symptoms and autonomic function ...

QIMA Life Sciences launches SQINGEVITY, bringing biological testing and clinical studies together to examine claims about ...

The whole-body scan company is launching a research network with 50+ institutions. Early findings come with some big open ...

The company added hormone therapy to its platform and released IBS results from nearly 16,000 members, with caveats attached.

Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well ...

Pharma has the podium as Novo and Lilly stop talking about GLP-1 longevity and start measuring it, bringing early aging data ...